Wilson Sonsini Goodrich & Rosati and Cooley advised Kura Oncology. Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Sagard Healthcare in the transaction, and Cooley represented MannKind Corporation. Sagard Healthcare (Sagard) announced it entered into a royalty purchase agreement, under which...
You must be a Standard 1 Year member to access this content.
Cooley advised Jiangsu Hengrui Pharmaceuticals on the deal. Jiangsu Hengrui Pharmaceuticals (“Hengrui”), a global pharmaceutical company focused on scientific and technological innovation, signed a global license agreement...
You must be a Standard 1 Year member to access this content.
Cooley advised Jiangsu Hengrui Pharmaceuticals on the deal. Jiangsu Hengrui Pharmaceuticals (“Hengrui”), a global pharmaceutical company focused on scientific and technological innovation, announced its strategic collaboration...
You must be a Standard 1 Year member to access this content.
Morrison Foerster advised Celadon Partners and GeneFab, while Cooley and Goodwin Procter advised Senti Biosciences. Senti Biosciences, Inc. (Nasdaq: SNTI) and Celadon Partners, LLC announced a transaction...
You must be a Standard 1 Year member to access this content.
Cooley advises ThoughtSpot on the deal. ThoughtSpot announced it has signed a definitive agreement to acquire Mode Analytics in a cash and equity deal valued at $200...
You must be a Standard 1 Year member to access this content.
Cooley advised Seven and Eight Biopharmaceuticals on the deal. Seven and Eight Biopharmaceuticals Inc. announced that it has signed an exclusive licensing agreement with Eikon Therapeutics....
You must be a Standard 1 Year member to access this content.
Cooley advised Impact Therapeutics on the deal. Impact Therapeutics and Eikon Therapeutics announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors...
You must be a Standard 1 Year member to access this content.
Cooley advised Zai Lab on the deal. Zai Lab, a research-based commercial-stage biopharmaceutical company, announced its strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics, as...
You must be a Standard 1 Year member to access this content.
Cooley advised Zion Pharma Limited on the deal. Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced the acquisition of its...
You must be a Standard 1 Year member to access this content.
Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Cooley advised SCYNEXIS on the deal. SCYNEXIS announced its exclusive license agreement with GSK for Brexafemme. The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp...
You must be a Standard 1 Year member to access this content.
